GlassScriptPhysician profile
David Lazzaro
NPI 1508589789
$3,543.02
in general payments reported to CMS, 2019-2025
24 companies · $1,966 in 2025
The $1,966 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $238 · 2023: $426 · 2024: $913 · 2025: $1,966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,106 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,106.31 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $652.79 | 2022-2025 | Xtandi, Veozah |
| Janssen Biotech, INC. | $638.28 | 2023-2025 | Erleada, Rybrevant, Carvykti |
| Sumitomo Pharma America, INC. | $384.51 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $265.34 | 2023-2025 | Lynparza, Keytruda |
| Tolmar, INC. | $212.43 | 2023-2025 | Eligard, Jatenzo |
| Ferring Pharmaceuticals INC. | $163.26 | 2025 | Adstiladrin |
| Boston Scientific Corporation | $156.72 | 2024-2025 | Ams 700, Spaceoar Vue System - 10ml |
| Urovant Sciences INC | $137.73 | 2022 | |
| Teleflex LLC | $116.33 | 2023-2025 | Barrigel, Urolift |
| Endo USA, INC. | $112.68 | 2025 | Aveed, Xiaflex |
| Pfizer INC. | $110.13 | 2024-2025 | |
| Coloplast Corp | $100.40 | 2025 | |
| Abbvie INC. | $96.31 | 2023-2025 | |
| Endo Pharmaceuticals INC. | $89.19 | 2023-2024 | Xiaflex, Aveed |
| Novartis Pharmaceuticals Corporation | $62.13 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $55.85 | 2023-2024 | Axonics, Bulkamid |
| Dendreon Pharmaceuticals LLC | $29.50 | 2025 | Provenge |
| 180 Medical, INC. | $25.44 | 2023 | Gentlecath |
| Immunitybio, INC. | $24.57 | 2025 | |
| Laborie Medical Technologies Corp. | $24.52 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Procept Biorobotics Corporation | $24.26 | 2024 | Aquabeam System |
| Myriad Genetic Laboratories, INC. | $22.74 | 2025 | Prolaris |
| Astrazeneca Pharmaceuticals LP | $21.76 | 2025 | Lynparza |
| Dentsply Ih Ab | $16.15 | 2023 | Lofric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lazzaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.